Current Drug Targets

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556


Targeting Toll-like Receptors in Autoimmunity

Author(s): K. S. Midwood, A. M. Piccinini and S. Sacre

Affiliation: Brighton and Sussex Medical School, Trafford Centre, Sussex University, Falmer, Brighton BN1 9RY, UK.


In the past few years there has been an increasing appreciation of the importance of Toll-like receptors (TLRs), not just in immunity, but also in autoimmune diseases. TLRs were first identified as sensors of viral and bacterial pathogens that form an integral part of the innate immune response. It was later discovered that these receptors can also respond to endogenous ligands that are produced as a result of tissue damage. This leads to the hypothesis that TLRs may be key contributors to the pathogenesis of chronic inflammatory conditions. A large body of data supporting the role of TLRs in autoimmunity has emerged from animal models and more data is increasingly being generated from human studies as further tools to examine these receptors have become available. Developing strategies to manipulate TLR function is of great interest in autoimmunity, as well as other diseases that include allergy and cancer. This review explores the evidence that points to a role for TLRs in autoimmunity and highlights some of the potential ways in which modulation of their action may yield clinical benefits.

Keywords: Toll-like receptors, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, antagonist, therapies

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [1139 - 1155]
Pages: 17
DOI: 10.2174/138945009789735101
Price: $58